Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la ...

Jean-Paul Kress to join Sanofi's Board of Directors Paris, . Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, ...

Sepsis is a life-threatening condition that happens when the body’s immune system has an extreme response to an infection.

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the ...

Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website: ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...

We’re using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design, and improving the manufacturing and supply of medicines and vaccines to get them to ...

Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session. We’re proud to ...

Across the stages of life, vaccination helps protect humanity from emerging epidemic and helps create and maintain healthy communities moving forward. Every year, vaccination saves up to 5 million ...

Sanofi US (Sanofi-Aventis U.S. LLC and Sanofi US Services Inc.) respects the interest that visitors to our websites have in understanding what information is collected electronically, how it is ...

Our manufacturing sites are state-of-the-art, powered by big data and digital. It is by producing vaccines that our mission takes on its full meaning. It is the bridge between scientific advances and ...

A Million Conversations is Sanofi’s global initiative to rebuild trust in healthcare with the underrepresented. Specifically with Black and ethnic minority groups, women, people with disabilities, and ...